Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.45 |
| ▸ | TTR | P02766 | 8/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749218 | 0.85 | ALDH1A1 (0.44) | RPS6KB1LPLLIPGNOTUMGAA | |
| SCHEMBL1749217 | 0.85 | ALDH1A1 (0.44) | RPS6KB1LPLLIPGNOTUMGAA | |
| SCHEMBL1749215 | 0.85 | ALDH1A1 (0.44) | RPS6KB1LPLLIPGNOTUMGAA | |
| SCHEMBL1749401 | 0.84 | MAPT (0.46) | RPS6KB1GAAMAPT | |
| SCHEMBL1749230 | 0.83 | RPS6KB1 (0.39) | RBP4TTRRPS6KB1LPLLIPG | |
| SCHEMBL1749277 | 0.83 | CHRM4 (0.40) | RBP4TTRRPS6KB1LPLLIPG | |
| SCHEMBL1750584 | 0.82 | CHRM4 (0.41) | RPS6KB1GAAMAPT | |
| SCHEMBL1749591 | 0.80 | NOTUM (0.48) | RBP4TTRNOTUMMAPT | |
| SCHEMBL21533025 | 0.80 | CKS1B (0.48) | — | |
| SCHEMBL1749694 | 0.77 | MAPT (0.52) | NOTUMGAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | RBP4 4650/4885TTR 2009/4885RPS6KB1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.